Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Pliant Therapeutics (PLRX) EBT (2020 - 2025)

Historic EBT for Pliant Therapeutics (PLRX) over the last 6 years, with Q3 2025 value amounting to -$26.3 million.

  • Pliant Therapeutics' EBT rose 5446.74% to -$26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$175.5 million, marking a year-over-year increase of 1298.19%. This contributed to the annual value of -$210.3 million for FY2024, which is 3035.16% down from last year.
  • Per Pliant Therapeutics' latest filing, its EBT stood at -$26.3 million for Q3 2025, which was up 5446.74% from -$43.3 million recorded in Q2 2025.
  • In the past 5 years, Pliant Therapeutics' EBT registered a high of -$22.8 million during Q2 2021, and its lowest value of -$57.8 million during Q3 2024.
  • Moreover, its 5-year median value for EBT was -$37.5 million (2023), whereas its average is -$37.8 million.
  • Per our database at Business Quant, Pliant Therapeutics' EBT tumbled by 30723.55% in 2021 and then surged by 5446.74% in 2025.
  • Quarter analysis of 5 years shows Pliant Therapeutics' EBT stood at -$24.5 million in 2021, then tumbled by 42.92% to -$35.1 million in 2022, then decreased by 17.25% to -$41.1 million in 2023, then dropped by 20.98% to -$49.7 million in 2024, then surged by 47.11% to -$26.3 million in 2025.
  • Its last three reported values are -$26.3 million in Q3 2025, -$43.3 million for Q2 2025, and -$56.2 million during Q1 2025.